Do current radical innovation measures actually measure radical drug innovation?
- PDF / 1,066,671 Bytes
- 30 Pages / 439.37 x 666.142 pts Page_size
- 48 Downloads / 213 Views
Do current radical innovation measures actually measure radical drug innovation? Ingo Stiller1,2 · Arjen van Witteloostuijn1,3 · Bart Cambré1 Received: 7 March 2020 © Akadémiai Kiadó, Budapest, Hungary 2020
Abstract To date, there has been little agreement in the literature on what exactly constitutes radical drug innovation and how to properly measure this important construct. Without a validated measure, our ability to understand radical drug innovations, explain their origins, and demonstrate their implications for management and health policy is limited. This paper addresses the problem of radical drug innovation measurement, provides evidence of the limitations associated with the current state of the art, and offers a new method based on German health technology assessments (HTA). Data was obtained for 147 drugs authorized by the European Medicines Agency from 2011 to 2016. The innovativeness of these drugs was assessed using current measures of radical drug innovation compared with the newly developed measure. Findings indicate that current measures of radical drug innovation are associated with very inconsistent outcomes and do not appear to measure what they purport to measure. This study argues that assessing therapeutic value (as measured by the German HTA) is particularly important, given that drug novelty alone does not conclusively indicate whether a drug will deliver therapeutic value. Keywords Radical innovation · Measurement · Health technology assessment · Pharmaceuticals
Introduction A large and growing body of literature focuses on the antecedents, processes, and impacts of radical innovation within a range of environments. More than 170 scholarly papers with the term radical innovation[1] in the title were published in the short period 1 Throughout this paper, the term radical innovation is used to describe rare and high-impact innovations, which provide competitive advantages to firms (Tushman and Anderson 1986). Other terms that are synonymous with radical innovation are breakthrough, major, and revolutionary innovations (Danneels and Kleinschmidt 2001).
The paper represents the author’s personal opinion and does not necessarily reflect the views of F. Hoffmann – La Roche AG or its staff. * Ingo Stiller [email protected] 1
Antwerp Management School and University of Antwerp, Antwerp, Belgium
2
F. Hoffmann – La Roche AG, Basel, Switzerland
3
School of Business and Economics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
13
Vol.:(0123456789)
Scientometrics
from January 2017 to January 2 019[2] alone in journals such as Research Policy, Journal of Knowledge Management, Academy of Management Proceedings, European Journal of Innovation Management, Journal of Organizational Change, and Public Management Review. This suggests that radical innovations are a central and popular topic across a variety of fields such as organization studies, management science, and public policy (Fagerberg et al. 2005; Gopalakrishnan and Damanpour 1997; Hagedoorn and Cloodt 2003; Jimén
Data Loading...
